DiaMedica Therapeutics (DMAC) Enterprise Value (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Enterprise Value for 9 consecutive years, with $336.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 143.67% year-over-year to $336.1 million; the trailing twelve-month figure through Jun 2026 stood at $336.1 million (up 143.67% YoY), and the FY2025 full-year result was $367.9 million, up 95.32% from the prior year.
• Enterprise Value improved to $336.1 million in Q2 2026 per DMAC's latest filing, from $313.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at $367.9 million in Q4 2025 and bottomed at -$3.3 million in Q3 2022.
• Historically, Enterprise Value has averaged $126.3 million across 5 years, with a median of $74.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value sank 111.67% in 2022, then surged 1661.82% in 2023.
• Over 5 years, Enterprise Value stood at $8.3 million in 2022, then surged by 563.27% to $54.9 million in 2023, then surged by 243.06% to $188.4 million in 2024, then surged by 95.32% to $367.9 million in 2025, then retreated by 8.63% to $336.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $336.1 million, $313.5 million, and $367.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.